Laurel Owens
Psychiatric/Mental Health · Lees Summit, MONPI 1104073907
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,030 of the $245,833 with a category attached, or 74.0%. Alkermes, Inc. accounts for 62.7% of it on its own, with 15 other manufacturers making up the rest. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,228 payments — averaging $200.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$154K
- AbbVie$85K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$895
- Teva Pharmaceuticals USA, Inc.$794
- Vanda Pharmaceuticals Inc.$664
- plus $3K from 10 others
What the payments were for
- Consulting fees$20,6258%
- Speaking & faculty fees$182,03074%
- Travel & lodging$25,91211%
- Food & beverage$17,1927%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 394 | $154,222 |
| AbbVie(2 entities) | 279 | $84,629 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 150 | $1,631 |
| Johnson & Johnson(2 entities) | 61 | $895 |
| Teva Pharmaceuticals USA, Inc. | 66 | $794 |
| Vanda Pharmaceuticals Inc. | 35 | $664 |
| Lundbeck LLC | 63 | $644 |
| Neurocrine Biosciences, Inc. | 33 | $529 |
| Otsuka America Pharmaceutical, Inc. | 46 | $519 |
| E.r. Squibb & Sons, L.L.C. | 46 | $462 |
| Indivior Inc. | 28 | $419 |
| Noven Therapeutics, LLC | 15 | $211 |
| Axsome Therapeutics, Inc. | 8 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Tonix Medicines, Inc. | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$346,984
- ARISTADA$252,477
- VRAYLAR$80,684
- ARISTADA INITIO$52,312
How this compares
$245,833 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 338 | $1,050,680 |
| LybalviOlanzapine/Samidorphan Malate | 409 | $656,570 |
| Invega SustennaPaliperidone Palmitate | 191 | $633,082 |
| AustedoDeutetrabenazine | 62 | $464,767 |
| IngrezzaValbenazine Tosylate | 28 | $305,017 |
| VraylarCariprazine Hcl | 162 | $234,437 |
| CaplytaLumateperone Tosylate | 126 | $204,925 |
| Invega TrinzaPaliperidone Palmitate | 16 | $148,758 |
| RexultiBrexpiprazole | 88 | $129,364 |
| TrintellixVortioxetine Hydrobromide | 209 | $104,531 |
| Abilify MaintenaAripiprazole | 35 | $93,640 |
| BelsomraSuvorexant | 90 | $43,229 |
| Paliperidone ErPaliperidone | 66 | $31,795 |
| VivitrolNaltrexone Microspheres | 16 | $28,058 |
| Clozapine | 269 | $16,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $154,222 | $1,735,309763 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $895 | $781,841207 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $794 | $464,76762 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $529 | $305,01728 claims |
| AbbVieVraylar | $84,629 | $234,437162 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $519 | $223,003123 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,631 | $204,925126 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $104,531209 claims |
| MerckBelsomra | $13 | $43,22990 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Lees Summit
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
- Karin BaughmanSpringfield$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.